Know Cancer

forgot password

A Pilot Phase II Study to Determine the Safety of the Combination of ONTAK (DAB389IL-2), an Interleukin-2 Fusion Toxin, in Combination With CHOP in Peripheral T-Cell Lymphoma

Phase 2
18 Years
Open (Enrolling)
Peripheral T-Cell Lymphoma

Thank you

Trial Information

A Pilot Phase II Study to Determine the Safety of the Combination of ONTAK (DAB389IL-2), an Interleukin-2 Fusion Toxin, in Combination With CHOP in Peripheral T-Cell Lymphoma

Inclusion Criteria:

- Pathological diagnosis of peripheral T-cell lymphoma of one of following histologies
as per the REAL classification: peripheral T-cell lymphoma (unspecified), anaplastic
large cell lymphoma CD30+, angioimmunoblastic T-cell lymphoma, nasal/nasal type T/NK
cell lymphoma, intestinal T-cell lymphoma, hepatosplenic T-cell lymphoma,
subcutaneous panniculitic T-cell lymphoma.

- Treatment naive except for prior radiation or a single cycle of CHOP.

- Patients must have at least one clear-cut bidimensionally measurable site by physical
exam and/or computed tomography. Baseline measurements of measurable sites and
evaluation of evaluable disease must be obtained within 4 weeks prior to registration
to this study.

- Prior radiation therapy for localized disease is allowed as long as the irradiated
area is not at the mediastinal area or at the only site of measurable disease.
Therapy must be completed at least 4 weeks before the enrollment in study.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

- Age > 18 years old.

- Adequate bone marrow reserve, indicated by absolute neutrophil count (ANC) ≥
1000/mm³, platelets ≥50,000/mm³(25,000/mm³ if thrombocytopenia secondary to bone
marrow involvement by lymphoma), and hemoglobin ≥8 g/dL. These values must be
obtained within 2 weeks before protocol entry.

- Adequate liver function, indicated by bilirubin ≤1.5 times the upper limit of normal
(ULN), alanine transaminase (ALT) ≤2 times the ULN or aspartate transaminase (AST)
≤2.0 times the ULN and albumin > 3.0 g/dl.

- Adequate renal function, indicated by serum creatinine ≤2.5 mg/dL. Laboratory values
must be obtained within 2 weeks before study entry.

- Women of childbearing potential and sexually active males are strongly advised to use
an accepted and effective method of contraception.

- Able to give informed consent.

Exclusion Criteria:

- Patients with diagnosis of Mycosis Fungoides or Sezary Syndrome

- Patients with active Hepatitis B or Hepatitis C infection.

- Patients with known HIV infection are excluded. These patients are excluded because
the potential to target activated T-cells, in a population of patients already at
risk for T-cell depletion, would be a contraindication to therapy. HIV testing is not

- Patients with active infections requiring specific anti-infective therapy are not
eligible until all signs of infections are resolved and any continuing treatment is
given on an outpatient basis.

- Patients with previous anthracycline therapy (cumulative dose of > 100 mg/m2).

- Patients with Left Ventricular Ejection Fraction (LVEF) < 50%.

- Patients who are pregnant or breast-feeding. These patients are excluded because the
effects of this treatment on the fetus and young children are unknown.

- Prior invasive malignancies within past 5 years.

- Allergic to or history of allergy to diphtheria toxin or IL-2.

- Preexisting severe cardiovascular disease (e.g. CHF, Severe CAD, cardiomyopathy, MI
within past 3 months, arrhythmia) requiring ongoing treatment.

- Ongoing antineoplastic chemotherapy, radiation, hormonal (excluding contraceptives)
or immunotherapy, or investigational medications within past 30 days.

- Patients with deep vein thrombosis within 3 months.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

safety and tolerability of the combination of ONTAK® (denileukin diftitox) and CHOP in newly diagnosed PTCL patients who are deemed candidates for chemotherapy by the investigators.

Outcome Time Frame:

upon completion of study

Safety Issue:


Principal Investigator

Francine Foss, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Yale University


United States: Institutional Review Board

Study ID:




Start Date:

November 2005

Completion Date:

November 2010

Related Keywords:

  • Peripheral T-cell Lymphoma
  • Lymphoma
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Peripheral



Yale Comprehensive Cancer Center at Yale University School of Medicine New Haven, Connecticut  06520-8064